Table 6.

Univariate Cox-regression analysis for predicting TTR and OS in 114 HCC patients with Microvascular Invasion with and without adjuvant Lenvatinib after PSM.

Variable	Univariate Analysis (TTR)			Univariate Analysis (OS)
	HR	95%CI	P	HR	95%CI	P
Age, years	0.99	0.97-1.01	0.312	0.99	0.96-1.01	0.291
Gender, Male vs. Female	0.64	0.26-1.62	0.350	0.65	0.23-1.83	0.415
HBV-DNA, IU/mL Negative vs. Positive	1.46	0.83-2.57	0.187	1.42	0.76-2.68	0.273
TBIL, µmol/L >2000 vs. ≤2000	1.32	0.70-2.48	0.388	1.21	0.59-2.47	0.605
ALB, g/L >35 vs. ≤35	0.89	0.28-2.87	0.848	0.71	0.22-2.31	0.573
ALT, U/L >44 vs. ≤44	0.77	0.43-1.37	0.380	0.64	0.33-1.24	0.187
PLT, ×109/L >100 vs. ≤100	0.85	0.40-1.81	0.674	0.71	0.33-1.55	0.396
PT, seconds >13 vs. ≤13	1.81	0.77-4.26	0.171	2.09	0.88-4.97	0.096
NLR >2.4 vs. ≤2.4	2.62	1.50-4.59	0.001	2.78	1.48-5.24	0.001
AFP, ng/mL >400 vs. ≤400	2.10	1.21-3.65	0.009	1.73	0.93-3.22	0.081
Transfusion Yes vs. no	1.64	0.94-2.86	0.079	1.45	0.78-2.70	0.242
Tumor diameter, cm >5 vs. ≤5	1.04	0.56-1.93	0.904	0.87	0.45-1.69	0.679
Tumor number Multiple vs. Single	1.41	0.75-2.65	0.288	1.54	0.77-3.08	0.222
Microvascular invasion M2 vs. M1	2.06	1.18-3.59	0.011	2.07	1.11-3.86	0.022
Tumor capsule Incomplete vs. Complete	0.60	0.33-1.07	0.084	0.69	0.36-1.30	0.246
Margin Wide vs. Narrow	0.55	0.31-0.96	0.035	0.51	0.27-0.94	0.031
Edmondson-Steiner grade III-VI vs. I-II	0.61	0.28-1.29	0.193	0.91	0.35-2.34	0.846
Cirrhosis Yes vs. No	1.60	0.89-2.87	0.114	1.43	0.75-2.74	0.273
Lenvatinib Yes vs. No	0.54	0.31-0.94	0.030	0.49	0.26-0.92	0.026

Bold values indicate statistical significance (P < 0.05). HCC, Hepatocellular Carcinoma; PSM, propensity score matching; OS, overall survival; TTR, time to recurrence; HBV-DNA, hepatitis B virus-deoxyribonucleic acid; TBIL, total bilirubin; ALB, albumin; ALT, Alanine aminotransferase; PT, Prothrombin time; PLT, platelet; NLR, neutrophil‐to‐lymphocyte ratio; AFP, alpha fetoprotein.